Supporting Access

A focus on generic injectables and biosimilars 

Our focus in Pharma has always been in generic injectables, and now, as we expand in Biopharma, we are also specializing in biosimilars. According to the Association for Accessible Medicines, FDA-approved generic and biosimilar medicines represent 90% of prescriptions dispensed in the U.S. but only 13.1% of total drug spending and just 1.2% of total U.S. health care spending.* Their use “created $445 billion in savings in 2023 for patients and the U.S. health care system — and over $3 trillion in savings the last ten years.”* 

At Fresenius Kabi, our teams gladly shoulder the responsibility of our essential role in driving affordability in healthcare. Every day, we find ways to offer more than 170 of these IV drugs at accessible costs. At the same time, we must ensure we have the resources to continue to add new drugs to our portfolio each year, with speed, as medicines go off-patent. We strive to be the first to bring generic alternatives of high-demand products to the market, as we consistently do in oncology, and in creating new categories such as generic contrast agents. And now we’re bringing the industry the cost benefits of biosimilars as well.   

*2024 U.S. Generic & Biosimilar Medicines Savings Report, Association for Accessible Medicines

Value-added packaging and administration technologies

Our focus on driving value and affordability in healthcare goes well beyond the types of drugs we produce, to our innovations in how we package them and the systems we develop to administer them. Our RFID and 2D labels can help reduce valuable time spent stocking and tracking medications, while our ready-to-administer products are designed to to help our customers in the areas of safety and ease of use.

Essential to the U.S. supply chain of care

As a company, Fresenius Kabi has always taken a long-term view, because medical professionals treating patients with critical and chronic conditions need us to be there for them not just today, but far into the future — and every day in between. Ensuring our customers have confidence in our ability to reliably deliver our products is why we invest heavily in our U.S. manufacturing and supply chain infrastructure, processes, and people. To this end, we have more than doubled the capacity of our three U.S. sterile injectable manufacturing sites in recent years, boosting our production and positioning us as a leading provider of these drugs in the U.S.

But we strive to look even further to find ways to support consistent performance across other aspects of the U.S. supply chain of care — most visibly in what our MedTech teams do for the transfusion medicine and biotherapy community. For decades we’ve been developing blood and plasma collection technologies that engage our customer’s donors and enhance their team’s productivity, to help make vital blood products more available to those who urgently need them. More recently, our cell and gene therapy manufacturing instruments are helping biotech innovators both develop the next generation of immunotherapies and realize their potential for patients, by enabling them to produce more cost-effectively, at scale, for widespread clinical use.

A leader in cross-industry collaborations

Because of our unique role in the health system, we recognize that drug supply challenges in the U.S. are bigger than any one organization. It’s why we serve on the boards of several forward-thinking, cross-industry organizations, including the End Drug Shortages Alliance and the Association for Accessible Medicines. It’s also why we actively engage with the FDA and GPOs and patient groups on supply continuity issues, and with leading medical institutions and societies looking for greater availability of alternatives for their patients.